| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.12 | 4e-05 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.12 | 4e-05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.13 | 8e-05 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.12 | 9e-05 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.0003 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |